1. Macroscopically normal human lung tissue was obtained from operative specimens removed for lung cancer and challenged with antigen or calcium ionophore. The release of histamine and slow-reacting substances was measured by fluorimetric and bioassay techniques respectively.
Introduction
For many years, slow-reacting substance of anaphylaxis (SRS-A) has been regarded as a putative mediator of allergen-provoked asthma because it is released from human lung tissue in vitro after antigen challenge [ l l and it causes contraction of isolated preparations of human bronchi [2, 31 and human peripheral lung [41. clinical asthma 161. Since a slow-reacting substance (SRS) which is indistinguishable from SRS-A is released from human lung tissue after non-immunological stimulation with the calcium ionophore A23187, it is possible that these substances may be involved in non-allergic asthma [71.
The leukotrienes, which are lipoxygenase products of arachidonic acid, have been identified recently as the active moieties in SRS-A and SRS [8, 91. Therefore, drugs which inhibit the lipoxygenase pathway may reduce leukotriene release from the lungs. Since benoxaprofen has been found to inhibit lipoxygenase and cyclooxygenase activity in rabbit polymorphonuclear leucocytes and in guinea-pig lung tissue [ lo], the present experiments were conducted to determine the effects of benoxaprofen in human lung tissue.
Materials and methods
The technique for preparation, sensitization and challenge of human lung fragments is described elsewhere [ 1 11. Briefly, macroscopically normal chopped lung tissue was incubated overnight at room temperature in human serum. Lung for challenge with A23187 was incubated in serum from normal subjects and serum with a high titre of immunoglobulin E to Dermatophagoides pteronyssinus (determined by the radioallergosorbent test) was used for passive sensitization of the lung for antigen challenge. 
0-
release of SRS and SRS-A into the supernatant was determined by bioassay with guinea-pig ileal strips and compared with a laboratory standard of partially purified SRS-A [ 1 1 I. Preliminary experiments indicated that these time intervals were optimal for the release of histamine, SRS and SRS-A. The laboratory standard was calibrated by bioassay with chemically synthesized leukotriene E, (LTE,) and 1 unit was equivalent to 1 a3 x 1O-Io mol of LTE,. The histamine content of the supernatant was measured by a modified fluorimetric method [71 and expressed as a percentage of the original tissue content after correction for spontaneous release. The composition of Tyrode solution was as follows (mmol/l): NaC1, 136.8; KCl, 2.7; MgSO,, 1.1; NaH,PO,, 0.5; CaCl,, 1-8; NaHCO,, 11.9; glucose, 5.3.
To determine the effects of benoxaprofen, lung ,fragments were pre-incubated at 37OC with dilutions of benoxaprofen (final concentrations 10-6-10-4 mol/l) in sodium chloride solution (154 mmol/l) for 15 min before addition of antigen or ionophore. In each experiment the release of SRS or SRS-A and histamine in the presence of benoxaprofen was compared with control release from lung fragments challenged with A23187 or antigen and results were expressed as a percentage of these control values.
Results
In experiments with antigen challenge of lung tissue obtained from six patients, the release of SRS-A ranged from 0.34 to 4-12 unitdm1 and the mean release of histamine was 40.9% (SEM 5.5; n = 6) of original tissue content. With calcium ionophore, the release of SRS ranged from 1 . 1 to 2.0 units/ml and the mean release of histamine was 47.1% (SEM 7.6; n = 5). The contractile effects of SRS and SRS-A on guineapig ileum were abolished by FPL55712 [ 121 in a concentration of 5 x low6 mol/l.
The effects of benoxaprofen on antigeninduced and ionophore-induced release of mediators are shown in Fig. 1 . In concentrations of 10-6-10-4 mol/l, benoxaprofen caused a dose-related statistically significant inhibition of SRS-A release without affecting histamine release. At the highest concentration of benoxaprofen ( lo-, mol/l) SRS-A release was reduced to a mean value of 37.0% (SEM 11.0; n = 6, P < 0405, paired t-test) of control values and the mean release of histamine was 89.7% (SEM 4.6; n = 6, P > 0.05 paired t-test).
Similarly, in experiments with the calcium ionophore, benoxaprofen caused a dose-related inhibition of SRS release without significantly altering histamine release. Benoxaprofen did not antagonize the action of the laboratory standard of SRS-A on guinea-pig ileum and A23187 (9.6 x mol/l) did not contract the bioassay tissues.
Discussion
The present experiments have shown that benoxaprofen, an inhibitor of the lipoxygenase pathway [ 101 caused a dose-related inhibition of SRS and SRS-A release from human lung tissue in vitro. Since the leukotrienes, which are lipoxygenase products of arachidonic acid [ In normal subjects, the plasma concentrations of benoxaprofen exceeded lou4 mol/l for more than 15 h after oral ingestion of 600 mg tablets 1 171, indicating that concentrations of benoxaprofen which caused significant inhibition of the lipoxygenase pathway in vitro may be achieved in vivo.
Other drugs currently available for the treatment of asthma, such as Padrenoceptor agonists, theophylline and cromoglycate, inhibit the release of both SRS-A and histamine 118, 191. In contrast, benoxaprofen has a selective inhibitory effect on SRS-A release without reducing histamine release. These findings in vitro suggest that benoxaprofen may be used to investigate the role of SRS-A in experimental and clinical asthma.
